Grifols Affirms Commitment to Patients During Alpha-1 Awareness Month
November is Alpha-1 Awareness Month, and Grifols is proud to share its efforts to further increase Alpha-1 diagnosis rates and expand treatment options.
Alpha-1 awareness matters. Alpha-1 Antitrypsin Deficiency (Alpha-1) is a genetic condition that may result in serious, chronic lung disease in adults, including an increased risk of developing emphysema, and is the most commonly known genetic risk factor for chronic obstructive pulmonary disease (COPD).
It may also result in liver disease for all ages, such as cirrhosis and liver cancer. It affects approximately 100,000 people in the U.S., but it is estimated that less than 10 percent of people living with Alpha-1 have been properly diagnosed, even though a simple blood test will detect the condition. Grifols is a leading global producer of plasma-derived medicines and a committed partner to the Alpha-1 community, dedicated to improving patients’ lives for 30 years.
Alpha-1 occurs when there is a lack of a protein in the blood called alpha-1 antitrypsin, or AAT. AAT is primarily produced in the liver and protects the lungs from infection and inhaled irritants. Alpha-1 is commonly misdiagnosed as asthma or smoking-related COPD. Left untreated, Alpha-1 can lead to liver and/or lung disease, which may be manifested as jaundice, liver failure, shortness of breath, chronic coughing due to COPD, chronic bronchitis, bronchiectasis, or severe asthma.
To view or download the Raising Alpha-1 Awareness infographic, please enter here.